What do we understand from the cooperation between Abbott, Roche and the Nine Strong?
M&A and splitting cooperation in the IVD field has been in full swing, as is the biochemical diagnostics market in the segment. Recently, the domestic biochemical reagent manufacturer Nine Strong Bio to the international top IVD company Abbott diagnostic output technology, this rare case of cooperation has been the focus of many industry insiders, but also caused some discussion. In the future, with the fierce competition in China's biochemical market, especially for the middle and low-end market, I believe that such cooperation will be more and more. At present, the largest in the in vitro diagnostic industry in China is immunodiagnosis and biochemical diagnosis, both of which account for more than 60%. Among them, immunodiagnosis accounts for the largest proportion of chemiluminescence, and foreign manufacturers have always been the market leader in this respect, accounting for about 60% of the market. The field of POCT and molecular diagnosis is also unique to foreign manufacturers, mainly due to technical barriers. The development of biotechnology abroad is fast and the technology conversion rate is high. It has been leading the global diagnostic technology innovation. In China's POCT market, the market share of foreign manufacturers is also over 60%, and foreign brands in the molecular diagnostic market account for more than 80%. At present, the best performance of domestic enterprises should be the biochemical market segment, and the biochemical diagnostic market is divided into biochemical instruments and biochemical reagent markets. The instrument market is still a higher share of foreign brands. Since the 1980s, biochemical diagnostic reagents have been As the reform and opening up brought in a large influx of foreign capital and foreign advanced technology, the domestic biochemical industry began the industrialization process, after the rapid development period from the 1980s to the 1990s, and the industry integration period from 1990s to 2000. From the industrial gold development period from 2000 to the present, the market concentration has been continuously improved, the market competition has gradually stabilized and orderly, and the technology update has accelerated. At present, various biochemical testing projects and corresponding reagents in the domestic biochemical industry are quite complete, and the biochemical analyzer technology is quite mature. Many technologies have reached the international advanced level. The quality of reagents of mainstream domestic brands is not much different from imported reagents, but it has a price advantage and is more easily accepted by hospitals. At present, the market share of domestic brands is over 60%. As an essential part of medical testing, biochemical diagnosis still maintains a large market share due to its low cost and high speed, and it is difficult to be replaced for a long time. In the future, due to the growth of the overall demand for medical care brought about by the aging of the country, the application of new testing projects brought about by technological advancement and the rapid expansion of the primary medical market after the gradual implementation of grading medical treatment, China's biochemical diagnostic market will continue to maintain rapid stability. Growth trend. As early as December 2013, Abbott and Jiuqiang Bio signed a strategic cooperation agreement for biochemical reagents in China. Abbott’s biochemical analyzer began to link sales models in China and the top nine biochemical reagents. In 2015, the two companies signed the technology in a logical way. Transfer agreement. In fact, in addition to Abbott, other major foreign companies have been carrying out similar localization strategies. Roche invested 450 million Swiss francs (about 3 billion yuan) to establish the first Roche diagnostic production base in the Asia-Pacific region in Suzhou Industrial Park. The products mainly include immunological and biochemical testing products, which will be fully operational by 2018. In March 2016, Roche and the Nine Strong cooperated on biochemistry. The Nine Strongs supplied biochemical reagents for cobas c701/702, cobasc 501/502, cobasc 311, Modular P and other instruments according to Roche's diagnostic requirements. Sales in China, the first batch of cooperation projects are 21 products. Roche Diagnostics has been seeking to localize to further reduce costs to gain price advantage and further enhance market competitiveness. At the same time, Roche Diagnostics China has continuously carried out service marketing strategies to strengthen terminal services, and continuously practice and improve its service system through sales support, application support, maintenance services, and reagent distribution. Lishida White Rice Vinegar is mainly used for pickling,making salads,sweet and sour dishes and sushi foods.Brewed from rice and other high quality ingredients,many families cook sweet & sour spare ribs,fish with this great vinegar.Welcome to share your recipes for white rice vinegar to us and people loving cuisines! White Rice Wine,Chinese White Vinegar,Rice Vinegar White Vinegar,White Rice Wine Vinegar KAIPING CITY LISHIDA FLAVOURING&FOOD CO.,LTD , https://www.lishidafood.com